As per the updates, Genta Incorporated ( OTC: GNTA ) announced that it will discuss the results of Phase III randomized controlled trial (AGENDA trial) of Genasense(R) Injection in patients with advanced melanoma in May 2011 and a more extended analysis of efficacy and safety from AGENDA will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in June 2011.

These 2 events are being carefully eyed by traders or penny stock pickers as it will raise very good opportunity for penny stock traders and as the events get closer , one might see a increase in share movements during the intraday. Be eyed on the stock for having a decent gains out of it. For more details 

read here. Stay tuned for more updates.